This Phase 2 study is testing a combination of two treatments, VV1 and cemiplimab, for certain types of cancer that have continued to grow despite previous immunotherapy. The study aims to see how well this combination shrinks tumors and if it is safe. You might be able to join if you are at least 18 years old and have melanoma, head and neck squamous cell carcinoma (a type of head and neck cancer), or colorectal cancer. However, the colorectal cancer and melanoma groups are currently closed to new patients. The main goal is to measure how many patients experience their tumors shrinking (objective response rate) within 24 months. This study is currently not recruiting new patients for all groups.

Study design

This is a Phase 2 interventional study planning to enroll 87 participants across three cancer groups. It uses a specific design called Simon's two-stage design.

What's involved

You would receive VV1 as an injection directly into your tumor and cemiplimab through an IV. Treatments would occur every 3 weeks until the treatment is no longer beneficial or causes too many side effects, with efficacy checked every 6 weeks.

Compensation

Not stated in the trial record.

Follow-up

The main measure of success (objective response rate) will be assessed within 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.